TIP_link_300x300.jpg
GMP Cytokines Market to Outstrip $158.13 Million by 2027 Growing Sturdy at 8.1% CAGR - COVID-19 Impact and Global Analysis by TheInsightPartners.com
June 11, 2021 09:38 ET | The Insight Partners
Pune, India., June 11, 2021 (GLOBE NEWSWIRE) -- GMP Cytokines Market: Key InsightsAccording to our new research study on “GMP Cytokines Market to 2027 – Global Analysis and Forecast – by Type,...
AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics
May 19, 2021 13:10 ET | AGC Biologics
Seattle, May 19, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for...
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma establishes Center of Excellence for cell and gene therapy in the UK
February 11, 2021 04:10 ET | Rentschler Biopharma SE
New enterprise, Rentschler ATMP Ltd., is part of continuous innovation at Rentschler Biopharma and supports ongoing strategic international expansionCenter of Excellence to address the gap in capacity...
Rentschler Biopharma logo from PR.jpg
Rentschler Biopharma to build new cell and gene therapy capabilities in the UK Rentschler Biopharma will establish their ATMP development and manufacturing capabilities at the Cell and Gene Therapy Catapult facility in StevenageAgreement confirms UK’s global attractiveness for...
Emergen logo.png
Cell and Gene Therapy Market Size to Reach USD 7,250.0 Million by 2028 | Increasing Investments in Production Capacity Expansion for Cell and Gene Therapy will be the Key Factor Driving the Industry Growth, States Emergen Research
January 26, 2021 05:38 ET | Emergen Research
Vancouver, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) -- The global cell and gene therapy market is projected to reach a market size of USD 7,250.0 Million by 2028 at a rapid and steady CAGR...
IVS-001 Logo RGB FNL.jpg
iVexSol Announces Series A Funding
December 01, 2020 08:00 ET | iVexSol Intelligent Vector Solutions
WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- iVexSol, a rapidly growing lentiviral vector (LVV) manufacturing company, today announced the closure of a $13.0M Series A funding round. A total...
NOVARTIS logo.jpg
Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia
October 30, 2020 02:15 ET | Novartis International AG
Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia Novartis global CAR-T manufacturing footprint now spans...
Alliance Reg Med.png
The Alliance for Regenerative Medicine Announces Its 2020 Cell & Gene Meeting on the Mesa Goes Virtual
June 24, 2020 11:44 ET | Alliance for Regenerative Medicine
Washington, DC, June 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The Alliance for Regenerative Medicine (ARM), an international multi-stakeholder advocacy organization representing the...
NOVARTIS logo.jpg
AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
May 19, 2020 01:15 ET | Novartis International AG
Zolgensma® (onasemnogene abeparvovec) is conditionally approved in Europe for the treatment of patients with spinal muscular atrophy (SMA) and a clinical diagnosis of SMA Type 1; or SMA patients with...
NOVARTIS logo.jpg
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
April 22, 2020 01:15 ET | Novartis International AG
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults...